title: Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
abstract: The most effective regimen for taxane- and anthracycline-refractory triple-negative breast cancer (TNBC) has not yet been established. Capecitabine was approved by the US Food and Drug Administration for the treatment of advanced breast cancer and has shown efficacy in advanced breast cancer refractory to anthracyclines and taxanes. Irinotecan has synergism with 5-fluorouracil and shows efficacy in advanced breast cancer. Here we report on a patient with TNBC who relapsed with widespread bone and lung metastases shortly after adjuvant anthracycline followed by taxane chemotherapy. She achieved a metabolic complete response with irinotecan and capecitabine combination therapy and had 10 months' progression-free survival and 22 months' overall survival. She relapsed with and died of brain metastasis without any definite signs of progression of the lung and bone lesions she had had before the irinotecan and capecitabine combination therapy. To validate this favorable result, larger clinical trials are warranted in patients with metastatic or relapsed TNBC.
authors.affiliation: Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju - Korea.
authors.forename: Anna
authors.initials: A
authors.lastname: Lee
authors.forename: Se-Il
authors.initials: SI
authors.lastname: Go
authors.forename: Won Sup
authors.initials: WS
authors.lastname: Lee
authors.forename: Un Seok
authors.initials: US
authors.lastname: Lee
authors.forename: Moon Jin
authors.initials: MJ
authors.lastname: Kim
authors.forename: Myoung Hee
authors.initials: MH
authors.lastname: Kang
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.forename: Hoon-Gu
authors.initials: HG
authors.lastname: Kim
authors.forename: Jung Hun
authors.initials: JH
authors.lastname: Kang
authors.forename: Kyung-Nyeo
authors.initials: KN
authors.lastname: Jeon
authors.forename: Jae Min
authors.initials: JM
authors.lastname: Cho
authors.forename: Jeong-Hee
authors.initials: JH
authors.lastname: Lee
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069287:Capecitabine; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D010384:Pelvic Bones / Q000000981:diagnostic imaging / Q000473:pathology*; D049268:Positron-Emission Tomography; D012008:Recurrence; D043823:Taxoids / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery*
chemical_list: D018943:Anthracyclines; D043823:Taxoids; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin